Advisory · Gastroenterology
IBD and liver disease drive the majority of GI deal activity.
Ambrosia provides senior-led advisory for gastroenterology licensing, M&A, and strategic partnerships — backed by a proprietary database of 40 verified gastroenterology transactions.
Deal Landscape
What gastroenterology transactions actually look like.
Verified Transactions
40
Median Upfront
$55M
Key Structure Insight
IBD biologics and MASH/NASH represent distinct deal structure patterns
Related Insights
Research relevant to gastroenterology.
Stay Informed
Get new deal intelligence and transaction insights as we publish them.
No spam. Unsubscribe anytime.
Discuss your gastroenterology transaction.
We’ll meet you at peer level — anywhere in the world.